Detalles de la búsqueda
1.
Impact of a Purified Microbiome Therapeutic on Abundance of Antimicrobial Resistance Genes in Patients With Recurrent Clostridioides difficile Infection.
Clin Infect Dis
; 78(4): 833-841, 2024 Apr 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37823484
2.
Manufacturing Processes of a Purified Microbiome Therapeutic Reduce Risk of Transmission of Potential Bacterial Pathogens in Donor Stool.
J Infect Dis
; 228(10): 1452-1455, 2023 11 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37540090
3.
Prevalence of Comorbid Factors in Patients With Recurrent Clostridioides difficile Infection in ECOSPOR III, a Randomized Trial of an Oral Microbiota-Based Therapeutic.
Clin Infect Dis
; 77(11): 1504-1510, 2023 11 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-37539715
4.
Safety and Tolerability of SER-109 as an Investigational Microbiome Therapeutic in Adults With Recurrent Clostridioides difficile Infection: A Phase 3, Open-Label, Single-Arm Trial.
JAMA Netw Open
; 6(2): e2255758, 2023 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36780159
5.
SER-109: An Oral Investigational Microbiome Therapeutic for Patients with Recurrent Clostridioides difficile Infection (rCDI).
Antibiotics (Basel)
; 11(9)2022 Sep 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-36140013
6.
Racial/Ethnic Differences in Insulin Resistance and Beta Cell Function: Relationship to Racial Disparities in Type 2 Diabetes among African Americans versus Caucasians.
Curr Obes Rep
; 4(2): 241-9, 2015 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-26627219
Resultados
1 -
6
de 6
1
Próxima >
>>